ClinicalTrials.gg
CompletedNCT03320694Updated Oct 27, 2017

Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus

A Phase 3 interventional study of Metformin and Insulin in Gestational Diabetes Mellitus in Pregnancy, sponsored by Services Institute of Medical Sciences, Pakistan. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-27.

Sponsored by Services Institute of Medical Sciences, Pakistan · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Feb 2016, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
278
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.

Enrollment
7th of 39
278 · median 112
Started
2016
with 3 others
Phase 3
12 of 39
none open now
Registered
27th of 39
by date

Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 7th largest by enrollment, is one of 4 that started in 2016, is one of 12 in phase 3, and was the 27th registered.

Diabetes, Gestational

877 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 134 Diabetes, Gestational studies recruiting now, 62 (46%) set no upper age limit and 70 (52%) stop at 75 or younger; 13 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing metformin in Diabetes, Gestational, or all of them as a file.
02

Study summary

Gestational diabetic mellitus (GDM) patients randomised to metformin or insulin group.Aim was to achieve blood sugar levels of Blood sugar fasting (BSF) \<5.3 mmol/l and 1 hour post meal\<7.8mmol/l. Both groups were followed till delivery and outcome studied.

Read the detailed description

75 gm Oral Glucose Tolerance Test (OGTT) was done in pregnant patients. Blood sugar fasting(BSF) > 5.5 mmol/l \& 2 hours postprandial >7.8 mmol/l was labelled as GDM. They were randomised to metformin or insulin group. Those assigned to metformin group were started metformin 500mg twice daily \& increased until 2500mg depending on the blood sugar levels. Aim was to achieve blood sugar levels of BSF \<5.3 mmol/l and 1 hour post meal\<7.8mmol/l. If blood sugar levels were not controlled, insulin was added. The insulin group was given 3 injections of regular insulin \& one intermediate acting insulin injection at night subcutaneously. Both groups were followed till delivery and outcome studied

03

Conditions studied

  • Gestational Diabetes Mellitus in Pregnancy

Keywords

  • Gestational Diabetes Mellitus, Metformin, Insulin
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:•

  • All pregnant Diagnosed GDM in pregnancy by OGTT from 22 week to 34 week with singleton pregnancy

Exclusion Criteria:

  • Patients with Known diabetes mellitus
  • Patients with multiple pregnancy
  • With essential hypertension or pre eclampsia
  • Patients having fetal malformation incompatible with life
  • Patients with intrauterine death of fetus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
278 participants (actual)

Study arms

  • Experimental
    metformin

    Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery

    Drug: Metformin

  • Active comparator
    Insulin

    Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery

    Drug: Insulin

Interventions

  • metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery

    Also known as: Glucophage

  • The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery

    Also known as: Humulin R U 100 and Humulin N

06

What researchers measure

Primary outcomes

  1. maternal glycemic control

    Maternal glycemic control was measured by blood sugar levels

    Time frame: From time of randomisation till 40 weeks

Secondary outcomes

  1. Fetal macrosomia

    Birth weight more than 4kg

    Time frame: at birth

  2. Apgar score

    \<7 at 5min

    Time frame: at birth

  3. Neonatal intensive care unit (NICU) stay

    Admitted to NICU

    Time frame: >24 hours after birth

  4. Perinatal death

    Fetal or neonatal death within 7 days

    Time frame: 7 days of delivery

  5. mode of delivery

    Lower segment cesarean section , Spontaneous Vaginal Delivery, Instrumental delivery

    Time frame: at delivery

  6. Neonatal hypoglycemia

    Neonatal blood sugar was checked at birth and if \<2.2mmol/l, was labelled

    Time frame: at birth

07

Study locations

1 site
  • Services Institute of Medical Sciences
    Lahore, Punjab, Pakistan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jun 2017, 16 months.

Of 14 phase 3 interventional studies under Diabetes, Gestational, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2017
First posted
Oct 25, 2017
StartActual
Feb 1, 2016
Primary completionActual
Jun 30, 2017
CompletionActual
Jun 30, 2017
Last update
Oct 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03320694
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Responsible party
Tayyiba Wasim (Professor Obs Gynae, Services Institute of Medical Sciences, Pakistan) — Principal investigator
First posted
Oct 25, 2017
Start date
Feb 1, 2016
Primary completion
Jun 30, 2017
Completion
Jun 30, 2017
Last update
Oct 27, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion